Testing HLX43 for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread or cannot be removed by surgery.
- Your cancer has continued to grow after at least one standard treatment, or you couldn't tolerate that treatment.
- You are willing to provide a tumor sample (from a past surgery or a new biopsy) to check for PD-L1.
- You are between 18 and 75 years old and in generally good health (able to perform daily activities).
- You have not had certain other cancers, serious lung or heart problems, or active infections in the recent past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests two new investigational drugs combined with either another experimental drug or an approved immunotherapy for advanced colorectal cancer that has stopped responding to standard chemotherapy. The goal is to see if these combinations can shrink tumors or slow cancer growth more effectively, and what side effects they may cause.
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This study tests an experimental drug called HLX43 in people with advanced pancreatic cancer that has not responded to at least one previous treatment. The drug may help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.